Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

n the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have shown that M6G given intravenously produces equivalent analgesia to morphine to combat post-operative pain. Studies have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. Other studies published recently in the scientific literature demonstrate that M6G also reduces respiratory depression compared to morphine.

M6G022 Study Design

The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the "gold standard" drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatme
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/14/2009)... 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food ... therapy for patients suffering from gallstones in whom ... disease or advanced age. ,, Chenodal prescriptions have ... Centric Health Resources ("Centric"), a specialty pharmacy company. ...
(Date:12/14/2009)... Dec. 14 Travelers of Interstate 70 west ... become a bit more colorful when 10 multicolored art ... is named going home , will eventually include ... a graduate student at Herron School of Art and ... Public Life. ,, Eli Lilly and Company (NYSE: ...
(Date:12/14/2009)... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... of directors with the addition of Lt. Gen. Ronald ... chairman of Martin, Blanck & Associates, a federal health ... his addition, the company board now has nine members. ... as a medical officer and battalion surgeon in Vietnam. ...
Breaking Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 1Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 1AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 3
... FRANCISCO, Calif., Nov. 6 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... the,company,s novel oral Factor Xa inhibitor and ... presented at the American Heart Association,(AHA) Scientific ...
... Bavarian,Nordic has completed a clinical safety report from a ... that confirms the excellent,safety profile of IMVAMUNE(R). Within the ... be submitted to the FDA and this will trigger ... The clinical safety,report constitutes a major part of the ...
Other Medicine Technology:Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008 2Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
(Date:12/15/2009)... DALLAS Dec. 15, 2009 UT Southwestern ... account to date of the unique observable characteristics ... aging syndrome. , The findings, reported online and ... of Clinical Endocrinology and Metabolism, suggest that ... be lumped together with those diagnosed with two ...
(Date:12/14/2009)... ANN ARBOR, Mich., Dec. 14 ... and the Commonwealth of Kentucky are among the ... solution this fall to help their employees make ... Enrollment solution gives employees a personalized summary of ... cost of that care. With this personalized information, ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... gardening replaced tube watching , , MONDAY, Dec. 14 (HealthDay ... hours of television a week until he enrolled in ... time in half. , During his enforced period of ... not necessarily through strenuous exercise, although he did find ... time was spent reading and working on the computer, ...
(Date:12/14/2009)... Statement of Steve Pasierb, President ,, NEW ... of Michigan,s Monitoring the Future study (MTF) -- the ... 8th, 10th and 12th graders -- underscores that teens, ... continues to be a cause for concern, with an ... from friends and relatives. ,, Teen ...
Breaking Medicine News(10 mins):Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Cutting TV Time Burns More Calories 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3
... of ban on their export of seafood to Canada as ... the banned chemical Malachite green in the fish tissues.// ... follow strict stringent rules and should test all batches of ... Malachite green and its byproducts. Consumer Association of Canada feels ...
... a deadly potion was brought home in a very uncomfortable ... of the greatest footballers' died in London yesterday. // ... own liver failed in the aftermath of his boozing exploits. ... world over, mostly male, suffer from alcohol-related liver disease each ...
... Insulin like-Growth Factor (IGF-1) is required for both ... secretion of IGF is mediated by the pituitary ... and is associated with metabolic abnormalities including insulin ... drugs helps in production of IGF-1 in children’s ...
... view, of the ever-increasing threat about bird flu worldwide, there ... manufacture the drug.// Ranbaxy Laboratories has become the first Indian ... drug, Tamiflu. The drug is believed to get shipped to ... Roche would be invalid. ,We have sent small ...
... prices and breakdown of electricity supplies, upto 90,000 senior ... have warned.//,As the Meteorological Office has issued its second ... gas - essential to warm homes - while some ... winter. ,Charity organisations caring for the elderly warned ...
... ideal sleeping position for toddlers with a new study ... when they sleep on their backs rather than on ... likely to be experienced by children who have sleep ... ,The study observed nearly 60 ...
Other Medicine News:Health News:Harsh British Winter Could Kill Upto 90,000 Pensioners 2
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: